Cue biopharma reports new complete response and confirmed 50% overall response rate in ongoing phase 1 trial of cue-101 and pembrolizumab in recurrent/metastatic hpv+ head and neck cancer

Additional complete response (cr) observed in patient with multiple tumors confirmed overall response rate (orr) of 50% in patients with combined positive score (cps) ≥1, including 50% orr in patients with low cps (1-19) 12-month overall survival of 88% and median overall survival (mos) of 32 months boston, july 16, 2025 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of autoimmune disease and cancer, today provided a clinical update on its most advanced asset, cue-101, representative of the cue-100 series. “we are excited to report an additional cr in a patient that had recurrent metastatic hpv+ head and neck squamous cell carcinoma (hnscc) treated with cue-101 in combination with pembrolizumab (keytruda®),” said matteo levisetti, chief medical officer at cue biopharma.
CUE Ratings Summary
CUE Quant Ranking